FDA: HHS, FDA and USDA address the health risks of ultra-processed foods
23 luglio 2025
Leggi
Breaking news
Tirzepatide treatment and associated changes in β-cell function and insulin sensitivity in people with obesity or overweight with prediabetes or normoglycemia: a post hoc analysis from the SURMOUNT-1 trial
Mari A, Stefanski A, van Raalte DH, et al.
Diabetes Care. 2025:dc250763.
Leggi
Global perspectives on monogenic forms of diabetes
Russ-Silsby J, Teles M, Hassan SS, et al.
Diabetologia. Pub online 16 Jul 2025.
Leggi
Delayed hypertension diagnosis and its association with cardiovascular treatment and outcomes
Lu Y, Brush JE, Kim C, et al.
JAMA Netw Open. 2025;8(7):e2520498.
Leggi
The efficacy of sodium-glucose cotransporter 2 inhibitors in reducing repeated heart failure rehospitalizations among elderly patients with acute decompensated heart failure: the ROSES-HF study
Amioka M, Kinoshita H, Fuji Y, et al.
Am J Cardiol. 2025 Jul:S0002-9149(25)00404-7.
Leggi
Interleukin-6 in heart failure with reduced ejection fraction and the effect of dapagliflozin: an exploratory analysis of the dapagliflozin and prevention of adverse outcomes in heart failure trial
Docherty KF, McDowell K, Welsh P, et al.
JACC Heart Fail. 2025;13(7):102393.
Leggi
Treating sarcopenic obesity in the era of incretin therapies: perspectives and challenges
Chen AS, Batsis JÁ
Diabetes. 2025:dbi250004.
Leggi
Stem cell-derived pancreatic beta cells: a step closer to functional diabetes treatment?
Ogieuhi IJ, Agbo CE, Ajekiigbe VO, et al.
BMC Endocr Disord. 2025;25(1):181.
Leggi
Challenges and opportunities for understanding the pathogenesis of type 1 diabetes: an Endocrine Society Scientific Statement
Michels AW, Brusko TM, Evans-Molina C, et al.
J Clin Endocrinol Metab. 2025:dgaf267.
Leggi
Neurodegeneration and stroke after semaglutide and tirzepatide in patients with diabetes and obesity
Lin HT, Tsai YF, Liao PL, et al.
JAMA Netw Open. 2025;8(7):e2521016.
Leggi